Source:http://linkedlifedata.com/resource/pubmed/id/21048934
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
10
|
pubmed:dateCreated |
2010-11-4
|
pubmed:abstractText |
Recent genome-wide association studies report that the SNP rs8099917, located 8.9 kb upstream of the start codon of IL28B, is associated with both disease chronicity and therapeutic response to pegIFN-? and RBV in patients infected with genotype 1 HCV. To determine the effect of rs8099917 variation on the response of HCV to therapy, we genotyped this variant in a cohort of 160 HCV/HIV-1 coinfected patients in our clinic unit who received combined peg-IFN-?/RBV therapy. The rs8099917 T/G or G/G genotypes were observed in 56 patients (35%). Treatment failure occurred in 80% of G-allele carriers versus 48% of non-carriers (P<0.0001). This result reveals that the G allele was strongly associated with treatment failure in this patient cohort. Importantly, a highly significant association was found between the G-allele and response to therapy in HCV genotype 1-infected patients (P<0.0001) but not in HCV genotype 3-infected patients. Multivariate analysis (odds ratio; 95% confidence interval; P value) indicated that the rs8099917 TT genotype was a strong predictor of treatment success (5.83; 1.26-26.92; P = 0.021), independent of baseline plasma HCV-RNA load less than 500 000 IU/ml (4.85; 1.18-19.95; P = 0.025) and absence of advanced liver fibrosis (5.24; 1.20-22.91; P = 0.025). These results reveal the high prevalence of the rs8099917 G allele in HCV/HIV-1 coinfected patients as well as its strong association with treatment failure in HCV genotype 1-infected patients. rs8099917 SNP genotyping may be a valid pre-treatment predictor of which patients are likely to respond to treatment in this group of difficult-to-treat HCV/HIV-infected patients.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:issn |
1932-6203
|
pubmed:author | |
pubmed:issnType |
Electronic
|
pubmed:volume |
5
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
e13771
|
pubmed:meshHeading |
pubmed-meshheading:21048934-Antiviral Agents,
pubmed-meshheading:21048934-Female,
pubmed-meshheading:21048934-HIV Infections,
pubmed-meshheading:21048934-HIV-1,
pubmed-meshheading:21048934-Hepatitis C,
pubmed-meshheading:21048934-Humans,
pubmed-meshheading:21048934-Interferon-alpha,
pubmed-meshheading:21048934-Male,
pubmed-meshheading:21048934-Middle Aged,
pubmed-meshheading:21048934-Polymorphism, Single Nucleotide,
pubmed-meshheading:21048934-Ribavirin,
pubmed-meshheading:21048934-Viral Load
|
pubmed:year |
2010
|
pubmed:articleTitle |
IL28B SNP rs8099917 is strongly associated with pegylated interferon-? and ribavirin therapy treatment failure in HCV/HIV-1 coinfected patients.
|
pubmed:affiliation |
Fundació irsiCaixa, Hospital Universitari Germans Trias i Pujol, Universitat Autonoma de Barcelona, Badalona, Barcelona, Spain.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|